Welcome to our dedicated page for GREY MATTERS HEALTH INC, news (Ticker: AGNPF), a resource for investors and traders seeking the latest updates and insights on GREY MATTERS HEALTH INC, stock.
Grey Matters Health Inc., formerly Algernon Health Inc. and Algernon Pharmaceuticals Inc., reports healthcare developments tied to its shift toward Alzheimer’s disease diagnostics and dedicated brain PET imaging. News for AGNPF has centered on NovaScan Neuroimaging Clinics, U.S. brain PET scanning center plans, CareMiBrain™ scanner technology, beta-amyloid detection, and clinical uses across dementia and other neurologic conditions.
Company updates also cover capital-structure actions, including name changes and share consolidation, equipment financing, service partnerships, clinic leases, and shareholder or governance matters. The company has also described Algernon NeuroScience’s regulated botanical wellness program involving a proprietary form of DMT and its equity interest in Seyltx, which is advancing Ifenprodil for chronic cough.
Summary not available.
Summary not available.
Summary not available.
Algernon Pharmaceuticals Inc. has received a Notice of Allowance from the USPTO for its patent application 17/258,402, which pertains to the treatment of Non-Alcoholic Steatohepatitis (NASH) using its lead drug, NP-251 (Repirinast). This significant allowance covers compositions and methods for treating non-alcohol fatty liver disease, supported by data showing Repirinast reduced hepatic fibrosis by 57% and NAFLD scores significantly. The company emphasizes that Repirinast is also a candidate for chronic kidney disease due to its efficacy in reducing fibrosis. In addition, Algernon aims to protect its intellectual property through international patent applications. This is a milestone for Algernon's drug repurposing program, according to CEO Christopher J. Moreau.
Algernon Pharmaceuticals has completed dosing the second cohort in its Phase 1 clinical study of an intravenous DMT formulation, AP-188. The study aims to assess safety, tolerability, and pharmacokinetics of DMT when administered via prolonged infusion. Following safety review committee approval, the final cohort will begin dosing soon. The study plans to include up to 60 volunteers, both experienced and inexperienced with psychedelics. The company is also collaborating with experts to prepare for Phase 2 trials aimed at treating brain injuries. Algernon has patented new formulations of DMT for potential stroke-related applications.
On April 3, 2023, Algernon Pharmaceuticals announced that its subsidiary, Algernon NeuroScience, qualified its Form 1-A offering statement with the SEC for a Tier II Regulation A+ offering. AGN Neuro plans to offer up to 37.5% of its common shares, primarily to fund its Phase 1 DMT study and upcoming Phase 2a studies for stroke and traumatic brain injury. Shares will be priced at USD $1 each, with various bonus share incentives for larger investments. The DMT program is valued at USD $20 million, based on market comparisons. A digital marketing campaign for the offering is expected to launch in early May 2023.
Algernon Pharmaceuticals Inc. is conducting a rights offering to raise approximately $2,416,747. Shareholders will receive 9,666,988 rights based on a ratio of one right per share held as of the record date of March 29, 2023. Each right allows the purchase of one unit at $0.25, which includes one share and one warrant exercisable at $0.52 for 18 months. The offering is aimed at providing existing shareholders a significant discount to incentivize participation. Trading of rights is set to commence on March 28, 2023, with an expiration on April 27, 2023. Proceeds will be allocated for working capital and general corporate expenses.
Algernon Pharmaceuticals Inc. (CSE: AGN) (OTCQB: AGNPF) announced the appointment of Dr. David L. Brody as a consultant for its Traumatic Brain Injury (TBI) clinical research program involving DMT (AP-188). Dr. Brody, a board-certified neurologist with extensive experience in TBI, previously served at Washington University and was involved in the NFL's neurological player care program. His collaboration aims to enhance the understanding and treatment of TBI, focusing on neuroplasticity amidst the lack of approved pharmacological options. Algernon NeuroScience, a subsidiary of Algernon, is seeking to raise up to $10 million for advancing its DMT research through a Tier II Regulation A+ offering.
Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: AGNPF) announced a four-for-one forward share split effective March 3, 2023, aimed at increasing liquidity. The current total of 2,413,431 Common Shares will rise to approximately 9,653,724 following the split. The CUSIP number will remain unchanged, and shareholders of record as of March 6, 2023, will receive DRS statements for the additional shares. Algernon is focused on drug development for unmet medical needs, with active programs in areas like chronic cough, chronic kidney disease, and innovative psychedelic research for neurological injuries.
Algernon Pharmaceuticals (CSE: AGN, OTCQB: AGNPF) announces a new clinical research program for Traumatic Brain Injury (TBI) using DMT (AP-188). The company aims to be the first to test DMT for TBI in humans, with a Phase 2 trial slated for Q4 2023. AGN Neuro has an ongoing Phase 1 DMT study in the Netherlands, having received positive safety assessments to move ahead. Key decisions for this program leverage DMT's neuroprotective qualities, with a focus on improving recovery in TBI patients. The company has appointed TBI expert Dr. Andrew Maas as a medical advisor to lend expertise to the research initiative, signaling commitment to addressing unmet needs in TBI treatment.